The user is experiencing hair loss despite using finasteride and Rogaine, with conflicting diagnoses from different hospitals. One suggests no hair loss, while another recommends continuing medication; a suggestion to see a dermatologist for proper assessment is given.
A 42-year-old user shared a 4-month update on their hair regrowth using a "nuclear stack" including oral and topical minoxidil, dutasteride, RU58841, micro-needling, keto shampoo, saw palmetto, biotin, multivitamins, scalp massages, and inversion table. They reported significant progress with minimal side effects and plan to continue the routine.
ShaneMorcs shared updated hair comparison photos and believes he's made progress. People commented on his improvement, asked about potential side effects, and inquired about the treatments he's using.
KX-826 Pyrilutamide 1% is launching soon, and users are discussing its potential benefits and drawbacks compared to other treatments like Minoxidil and finasteride. Some users are skeptical about its effectiveness, while others are hopeful it will be a safer alternative.
PP405 is a new hair loss treatment in phase 2 trials that may promote hair growth by increasing lactate production and activating hair follicle stem cells. It could potentially replace hormone-disrupting treatments like Minoxidil and finasteride.
A 22-year-old with high estradiol levels is considering starting finasteride for hair loss. They have an upcoming endocrinologist appointment to discuss whether they should proceed with the treatment.
User started minoxidil, noticed forehead lines and dark circles, and asked for non-invasive skin aging prevention methods. Another user suggested using tretinoin and hyaluronic acid for long-term benefits.
Hair loss treatments discussed include Minoxidil, Finasteride, and RU58841. HMI-115, a monoclonal antibody drug, is in phase 1 and 2 trials for different conditions, but its availability on the gray market is unlikely due to high production costs.
Minoxidil and microneedling are causing new hair growth, particularly in the center of the hairline, creating a more prominent M shape. Users discuss the progress and potential benefits of the treatment.
The conversation discusses using finasteride, dutasteride, minoxidil, and RU58841, along with a 10,000 graft hair transplant, to prevent magpies from targeting bald men. The title humorously references an eight-year-old's survey on magpies swooping bald men.
PP405 significantly improves hair density, outperforming finasteride, with 31% of users seeing over 20% improvement in four weeks. Concerns exist about its availability, cost, and long-term effects.
RU58841 is being mixed with Minoxidil solution, but concerns arise about water causing instability. Mixing with water may lead to hydrolysis, potentially reducing effectiveness.
A humorous discussion about random, long hairs appearing on the body, with no connection to hair loss treatments like Minoxidil, finasteride, or RU58841. Participants share personal anecdotes about these unusual hairs.
A 23-year-old male has been experiencing hair loss since 2022 and has used minoxidil and dutasteride with reduced shedding but no hair regrowth. He is considering PRP with mesotherapy and red light therapy, GFC, or exosomes, with a preference for exosomes due to efficiency and a reputable clinic.
A female user is considering using RU58841 with minoxidil 2.5% to reduce side effects like facial hair from minoxidil 5%, while also using copper peptides and a hair serum. Other users discuss alternative treatments like spironolactone, alfatradiol, and the side effects of finasteride.
The conversation discusses the delay in the PP405 Phase 2 study results, now expected by the end of 2025, and skepticism about research practices. There is also mention of optimism for Amplifica's AMP303 and a topical treatment in early testing.
The conversation is about a person's hair loss treatment routine, which includes Metformin, sleep in darkness, avoiding EMF at night, Nizoral, Dermarolling, Castor oil, and Collagen. They have observed less hair shedding and increased hair volume.
The post and conversation discuss Verteporfin's potential as a hair loss treatment. It's shown promise in regrowing hair after transplants and might be effective with microneedling.
Pyrilutamide is a selective AR antagonist with a high binding affinity, making it effective in competing with DHT for androgen receptors. The 1% concentration is more effective than the 0.5%, but the latter may suffice for mild hair loss; the drug is considered a good option for those avoiding 5AR blockers due to side effects.
PP405 shows promise in stimulating new terminal hair growth by activating dormant follicles, with no systemic adverse effects observed in a short-term trial. However, long-term efficacy remains unproven, and further trials are needed to confirm its potential as a hair loss treatment.
Adding non-prescription topicals like alfatradiol and Zix to a standard fin/min/niz regimen may help with scalp inflammation and shedding, but their long-term effectiveness varies. Zix is recommended for reducing scalp inflammation and enhancing the effectiveness of other treatments.
Chime Biologics and Hope Medicine are speeding up the launch of a first-in-class antibody drug, HMI-115, for endometriosis and androgenic alopecia. The treatment involves a series of subcutaneous injections, has shown promising results in phase 1, and continues to promote hair regrowth even after the treatment is stopped.
A 15% discount is offered on hair research products like RU58841 and TEMPOL at Chemyo.com. The legality of selling these compounds is confirmed by the seller.
A user discusses their experience with at-home microneedling at 1mm for hair growth, feeling like they're hitting their skull. Other users suggest lowering the needle depth or stopping due to discomfort.
Hair transplants for NW7 individuals are challenging due to limited donor hair, often resulting in thin coverage unless body or beard hair is used. Treatments like minoxidil and finasteride are mentioned to support hair density and growth.